Jairam Krishnamurthy
( out of 167 reviews )

Jairam Krishnamurthy, MD, FACP

Languages spoken: Hindi, English, Tamil

Dr. Jairam Krishnamurthy is a board-certified medical oncologist and hematologist with specialized expertise in the management of breast cancer across its diverse subtypes, including hormone receptor-positive, HER2-positive and triple-negative disease. He joined Huntsman Cancer Institute at the University of Utah in July 2025, as Associate Professor of Medicine in the Division of Oncology, Department of Internal Medicine. He holds the Huntsman Cancer Institute Endowed Chair in Women's Cancer Research.

At Huntsman Cancer Institute, Dr. Krishnamurthy leads the Breast Cancer Clinical Trials Research Group, where he is dedicated to building a comprehensive and inclusive clinical trial portfolio. His work encompasses industry-sponsored, cooperative group, and investigator-initiated studies, with a focus on expanding access to innovative therapies and promoting equitable participation in breast cancer research. As Co-Leader of the Breast and Gynecologic Cancer Center, Dr. Krishnamurthy fosters interdisciplinary collaboration between basic scientists and clinical teams, enhances operational efficiency across breast cancer services, and advances community outreach and engagement initiatives.

Prior to joining Huntsman Cancer Institute, Dr. Krishnamurthy served for a decade at the University of Nebraska Medical Center, where he was the Medical Director of the Breast Cancer Program and led the Breast Cancer Clinical Trials Research Group. He was Principal Investigator on numerous clinical trials, including several investigator-initiated studies he personally developed. Additionally, he served as Associate Director of the Hematology and Medical Oncology Fellowship Program for five years, mentoring fellows and junior faculty. From 2019 to 2025, Dr. Krishnamurthy was a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines Panel, contributing to the development of national standards in breast cancer care. Dr. Krishnamurthy's professional mission centers in delivering exceptional patient care, advancing access to cutting-edge research, supporting the career development of junior faculty, and mentoring the next generaltion of oncology professionals. He is enthusiastic about the opportunities in Huntsman Cancer Institute and remains committed to driving innovation and collaboration in breast cancer research and care.

Specialties

Board Certification

Educational Commission for Foreign Medical Graduates
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
American Board of Internal Medicine

Patient Rating

Patients consistently praise the physician for clear, thorough explanations that make complex information easy to understand. Many comments highlight his kindness, professionalism, attentiveness, and ability to make patients feel informed and comfortable about their care and next steps. Reviewers also note his strong knowledge of patient history, thoughtful care planning, and a supportive bedside manner complemented by caring staff.

Generated via Patient Reviews

4.9 /5
( out of 167 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.

May 17, 2026
HUNTSMAN CANCER CENTER

He is really smart and explained things really well. He tried to get me into a clinic study but the timing of it is not in our favor so that was disappointing. Overall he is excellent.

May 07, 2026
HUNTSMAN CANCER CENTER

Thank you for the care you provide.

Mar 25, 2026
HUNTSMAN CANCER CENTER

Very caring. Explains everything that is going on well.

Feb 16, 2026
HUNTSMAN CANCER CENTER

Dr, Krishnamurthy was clear with explanations and made sure we were well informed of what to expect with my upcoming care and procedures. He was impressively aware of my previous procedures and what was scheduled in the future. He answered all our questions with care.

Feb 09, 2026
HUNTSMAN CANCER CENTER

Great concern and cares about my questions and a good sense of humor. Really like him and his staff.

Jan 08, 2026
HUNTSMAN CANCER CENTER

Thank you for your kind treatment and explanations. [TRANSLATED]

Dec 14, 2025
HUNTSMAN CANCER CENTER

He is amazing. He knew my chronological profile better than I did.

Dec 11, 2025
HUNTSMAN CANCER CENTER

She is very professional; I liked her manner and her attention. Thank you very much for your professionalism. [TRANSLATED]

Aug 26, 2025
HUNTSMAN CANCER CENTER

Dr. Krishnamurthy is wonderful, and I can't say enough good things about him. He explained everything to me in a way that allowed me to understand exactly what is going on and what I can expect in the future, when it come to treatments and my cancer journey. He went above and beyond to make me feel comfortable and help me. I am very grateful that he is my doctor.

Aug 24, 2025
HUNTSMAN CANCER CENTER

The doctor was very thorough, explained things in great detail, but to understand. He is one of the best.

Aug 23, 2025
HUNTSMAN CANCER CENTER

Jairam Krishnamurthy, MD is a blessing to our family. He is extremely intelligent, kind, and shows a great deal of care towards his patients.

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

Dr. Jairam Krishnamurthy is a board-certified medical oncologist and hematologist with specialized expertise in the management of breast cancer across its diverse subtypes, including hormone receptor-positive, HER2-positive and triple-negative disease. He joined Huntsman Cancer Institute at the University of Utah in July 2025, as Associate Professor of Medicine in the Division of Oncology, Department of Internal Medicine. He holds the Huntsman Cancer Institute Endowed Chair in Women's Cancer Research.

At Huntsman Cancer Institute, Dr. Krishnamurthy leads the Breast Cancer Clinical Trials Research Group, where he is dedicated to building a comprehensive and inclusive clinical trial portfolio. His work encompasses industry-sponsored, cooperative group, and investigator-initiated studies, with a focus on expanding access to innovative therapies and promoting equitable participation in breast cancer research. As Co-Leader of the Breast and Gynecologic Cancer Center, Dr. Krishnamurthy fosters interdisciplinary collaboration between basic scientists and clinical teams, enhances operational efficiency across breast cancer services, and advances community outreach and engagement initiatives.

Prior to joining Huntsman Cancer Institute, Dr. Krishnamurthy served for a decade at the University of Nebraska Medical Center, where he was the Medical Director of the Breast Cancer Program and led the Breast Cancer Clinical Trials Research Group. He was Principal Investigator on numerous clinical trials, including several investigator-initiated studies he personally developed. Additionally, he served as Associate Director of the Hematology and Medical Oncology Fellowship Program for five years, mentoring fellows and junior faculty. From 2019 to 2025, Dr. Krishnamurthy was a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines Panel, contributing to the development of national standards in breast cancer care. Dr. Krishnamurthy's professional mission centers in delivering exceptional patient care, advancing access to cutting-edge research, supporting the career development of junior faculty, and mentoring the next generaltion of oncology professionals. He is enthusiastic about the opportunities in Huntsman Cancer Institute and remains committed to driving innovation and collaboration in breast cancer research and care.

Board Certification and Academic Information

Academic Departments Internal Medicine -Associate Professor (Clinical)
Academic Divisions Oncology
Board Certification
Educational Commission for Foreign Medical Graduates
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
American Board of Internal Medicine

Education history

Professional Medical Medicine - All India Institute of Medical Sciences M.D.
Internship All India Institute of Medical Sciences Intern
Residency Radiation Oncology - All India Institute of Medical Sciences Junior Resident
Residency Ophthalmology - All India Institute of Medical Sciences Junior Resident
Postdoctoral Fellowship Hematopoietic Stem Cell Transplantation Program - Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology Postdoctoral Research Fellow
Internship Internal Medicine - The Carle Illinois College of Medicine Intern
Residency Internal Medicine - Creighton University Medical Center Resident
Fellowship Oncology/Hematology - University of Nebraska Medical Center Fellow

Selected Publications

Journal Article

  1. Kesireddy M, Makos OL, DiMaio DJ, Krishnamurthy (2026). A Case of Pegfilgrastim-Induced Sweet Syndrome and Literature Review of Similar Cases. Case reports in oncological medicine,
  2. Shivam K, Allen J, Aljabrain F, Elliott, KJ, Krishnamurthy J, Kelley, (2026). Management of Bone Heath in Breast Cancer Survivors. JCO oncology practice,
  3. Pan T, Alimi OA, Liu B, Krishnan MA, Kuss M, Shi W, Krishnamurthy J, Dong JJ, Oberley-Deegan RE, Duan B (2025). Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. Reports (MDPI),
  4. William J. Gradishar, MD1,*; Meena S. Moran, MD2,*; Jame Abraham, MD3; Vandana Abramson, MD4; Rebecca Aft, MD, PhD5; Doreen Agnese, MD6; Kimberly H. Allison, MD7; Bethany Anderson, MD8; Janet Bailey, MD9; Harold J. Burstein, MD, PhD10; Nan Chen, MD11; Helen Chew, MD12; Chau Dang, MD13; Anthony D. Elias, MD14; Sharon H. Giordano, MD, MPH15; Matthew P. Goetz, MD16; Rachel C. Jankowitz, MD17; Sara H. Javid, MD18; Jairam Krishnamurthy, MD19; A. Marilyn Leitch, MD20; Janice Lyons, MD3,*; Susie McCloskey, MD, MSHS21; Melissa McShane, MD22; Joanne Mortimer, MD23; Sameer A. Patel, MD22; Laura H. Rosenberger, MD, MS24; Hope S. Rugo, MD25; Cesar A. Santa-Maria, MD, MSCI26,*; Bryan P. Schneider, MD27; Mary Lou Smith, JD, MBA28; Hatem Soliman, MD29; Erica M. Stringer-Reasor, MD30; Melinda L. Telli, MD7; Mei Wei, MD31,*; Kari B. Wisinski, MD8,*; Amulya Yellala, MBBS19; Kay T. Yeung, MD, PhD32,*; Jessica S. Young, MD33; Ryan Schonfeld, BA34,*; and Rashmi Kumar, PhD34, (2025). Invasive, Nonmetastatic Breast Cancer. Journal of the National Comprehensive Cancer Network, 23(11), 426-436.
  5. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar (2025). NCCN Guidelines® Insights: Breast Cancer, Version 5.2025. Journal of the National Comprehensive Cancer Network, 23(11), 426-436.
  6. Pan T, Alimi OA, Liu B, Krishnan MA, Kuss M, Shi W, Krishnamurthy J, Dong JJ, Oberley-Deegan RE, Duan (2025). Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. Pharmaceuticals (Basel, Switzerland), 18(8),
  7. Kesireddy M, Masih D, Shostrom VK, Yellala A, Asif S, Krishnamurthy (2025). Overall Survival and Prognostic Factors in De Novo Metastatic Human Epidermal Growth Factor Receptor (HER)-2-Positive Breast Cancer: A National Cancer Database Analysis. Cancers, 17(11),
  8. Alves TF, Crosby K, Horner RD, Dai HD, Krishnamurthy J, Cozad M (2025). Metastatic Breast Cancer mHealth App to Promote Patient-Provider Communication: Protocol for a Usability and Satisfaction Study. JMIR research protocols, 14, e66050.
  9. Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky R (2024). Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO precision oncology, 8, e2300513.
  10. Kesireddy M, Elsayed L, Shostrom VK, Agarwal P, Asif S, Yellala A, Krishnamurthy (2024). Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis. Cancers, 16(10),
  11. Jiang H, Cartwright S, Wagner DG, Krishnamurthy J, Santamaria-Barria J (2024). Pathologic Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Postpartum High-Risk Basal-Type Breast Cancer. Cureus, 16(6), e62338.
  12. Elsayed L, Reed E, Modi S, Tandra PK, Copur MS, Samson K, Krishnamurthy (2024). Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide with Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer. Clinical breast cancer, 24(8), 676-682.e1.
  13. Khandalavala B, Carlson S, Elsayed L, Geske J, Krishnamurthy (2024). Diet Quality in Patients with Breast Cancer: Results of a Single Cohort Study in a Midwestern US Population. . Nutrition and cancer, 1-9.
  14. Kuhlers SL, Kathol E, Hartnett-Quach D, Krishnamurthy J, Marth (2024). Assessing Outcomes of Tapering 12-Hour and 6-Hour Dexamethasone Prior to Paclitaxel Infusions in Patients with Breast Cancer. Clinical breast cancer,
  15. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar (2024). Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(5), 331-357.
  16. Davis AA, Luo J, Zheng T, Dai C, Dong X, Tan L, Suresh R, Ademuyiwa FO, Rigden C, Rearden TP, Clifton K, Weilbaecher K, Frith A, Tandra PK, Summa T, Haas B, Thomas S, Hernandez-Aya LF, Peterson LL, Wang X, Luo SJ, Zhou K, Du P, Jia S, King BL, Krishnamurthy J, Ma C (2023). Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer. Clinical cancer research, 29(9), 1719-1729.
  17. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Schneider B, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Young JS, Yeung K, Dwyer MA, Kumar (2023). NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. Journal of the National Comprehensive Cancer Network, 21(6), 594-608.
  18. Krishnamurthy J, Luo J, Suresh R, Ademuyiwa F, Rigden C, Rearden T, Clifton K, Weilbaecher K, Frith A, Roshal A, Tandra PK, Cherian M, Summa T, Haas B, Thomas S, Hernandez-Aya L, Bergqvist M, Peterson L, Ma C (2022). A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. NPJ breast cancer, 8(1), 35.
  19. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar (2022). Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20(6), 691-722.
  20. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar (2021). NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. Journal of the National Comprehensive Cancer Network, 19(5), 484-493.
  21. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18(4), 452-478.
  22. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18(4), 452-478.
  23. Kommalapati A, Tella SH, Goyal G, Ganti AK, Krishnamurthy J, Tandra P (2018). A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer. Breast cancer research and treatment, 170(3), 677-685.
  24. Bhatt VR, Shrestha R, Krishnamurthy J, Mosalpuria K, Loberiza FR Jr, Ganti AK, Silberstein PT (2015). Clinicopathologic characteristics and management trends of cutaneous invasive and in situ melanoma in older patients: a retrospective analysis of the National Cancer Data Base. Ther Adv Med Oncol, 7(1), 4-11.
  25. Bhatt VR, Loberiza FR Jr, Tandra P, Krishnamurthy J, Shrestha R, Wang J (2014). Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder. Rare Tumors, 6(1), 5043.
  26. Aryal MR, Bhatt VR, Tandra P, Krishnamurthy J, Yuan J, Greiner TC, Akhtari M (2014). Autoimmune neutropenia in multiple myeloma and the role of clonal T-cell expansion: evidence of cross-talk between B-cell and T-cell lineages? Clin Lymphoma Myeloma Leuk, 14(1), e19-23.
  27. Gonsalves WI, Tashi T, Krishnamurthy J, Davies T, Ortman S, Thota R, Aldoss I, Ganta A, Kalaiah M, Didwaniya N, Eberle C, Ganti AK, Silberstein PT, Subbiah S (2011). Effect of palliative care services on the aggressiveness of end-of-life care in the Veteran's Affairs cancer population. J Palliat Med, 14(11), 1231-5.
  28. Gonsalves WI, Kanuri S, Tashi T, Aldoss I, Sama A, Al-Howaidi I, Ganta A, Kalaiah M, Thota R, Krishnamurthy J, Fang X, Townley P, Ganti AK, Subbiah S, Silberstein PT (2011). Clinicopathologic factors associated with lymph node retrieval in resectable colon cancer: a Veterans' Affairs Central Cancer Registry (VACCR) database analysis. J Surg Oncol, 104(6), 667-71.
  29. Singh V, Krishnamurthy J, Duffey S, Meagher R, Villa M, Monreal J, Evens A, Frankfurt O, Altman J, Gordon L, Tallman M, Williams S, Winter J, Singhal S, Mehta J (2009). Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma? Bone Marrow Transplant, 43(4), 301-5.
  30. Singhal S, Vickrey E, Krishnamurthy J, Singh V, Allen S, Mehta J (2009). The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood, 114(1), 38-9.
  31. Mehta J, Mehta J, Frankfurt O, Altman J, Evens A, Tallman M, Gordon L, Williams S, Winter J, Krishnamurthy J, Duffey S, Singh V, Meagher R, Grinblatt D, Kaminer L, Singhal S (2009). Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma, 50(9), 1434-41.

Review

  1. Mainali NR, Bhatt VR, Kedia S, Krishnamurthy J, Wake LM, Akhtari M (2014). Reversible bone marrow aplasia induced by pegylated interferon-¿-2a therapy in a patient with primary myelofibrosis. [Review]. J Oncol Pharm Pract, 20, (5), 386-92.
  2. Tandra P, Krishnamurthy J, Bhatt VR, Newman K, Armitage JO, Akhtari M (2013). Autoimmune cytopenias in chronic lymphocytic leukemia, facts and myths. [Review]. Mediterr J Hematol Infect Dis, 5, (1), e2013068.
  3. Akhtari M, Bhatt VR, Tandra PK, Krishnamurthy J, Horstman H, Dreessen A, Chen PX, Armitage JO (2013). Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients. [Review]. Cancer Biol Ther, 14, (12), 1077-88.

Book Chapter

  1. Krishnamurthy J, Yellala (2023). General Considerations for Follow-Up.

Commentary

  1. Tandra P, Kallam A, Krishnamurthy (2019). Identification and Management of Lymphedema in Patients With Breast Cancer. Journal of oncology practice, 15(5), 255-262.
  2. Krishnamurthy J, Tandra P (2019). Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Common Complication With Effective Treatment Strategies. Journal of oncology practice, 15(7), 373-374.
  3. Krishnan M, Krishnamurthy J, Shonka (2019). Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain. Oncology (Williston Park, N.Y.), 33(8),

Case Report

  1. Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma C (2019). Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network, 17(2), 141-147.
  2. Kommalapati A, Kallam A, Krishnamurthy J, Tella SH, Koppala J, Tandra P (2018). Upper Limb Phlegmasia Cerulea Dolens Secondary to Heparin-induced Thrombocytopenia Leading to Gangrene. Cureus, 10(6), e2853.
  3. Ghosh S, Bendi VS, Krishnamurthy J, Tandra P, Kommalapati (2018). Type 2M Von Willebrand Disease: A Case Report. Cureus, 10(8), e3112.
  4. Kallam A, Krishnamurthy J, Kozel J, Shonka N (2015). Undifferentiated Embryonal Sarcoma of Liver. Rare Tumors, 7(4), 6009.
  5. Krishnamurthy J, Krishnamurty DM, Baker JJ, Zhen W, Lydiatt D, Ganti AK (2013). Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature. Head Neck, 35(12), E372-5.

Editorial

  1. Kesireddy M, Krishnamurthy (2025). T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective. Gland surgery, 14(4), 785-790.
  2. Kesireddy M, Krishnamurthy (2024). Pregnancy-Associated Breast Cancer: Key Concepts for Optimizing Diagnosis and Treatment. JCO oncology practice, OP2400867.

Abstract

  1. Alves TF, Crosby K, Horner RD, Dai HD, Krishnamurthy J, Cozad MJ (2025). Metastatic Breast Cancer mHealth App to Promote Patient-Provider Communication: Protocol for a Usability and Satisfaction Study. . 8;14(1):e66050,
  2. Louthan D, Sharifi MN, Danciu OC, Krishnamurthy J, Vasekar MK, Hoskins K, Lasarev M, Eikhoff J, O¿Regan RM, Wisinski KB, Truica CI (2025). Alpelisib (BYL719) with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (BTCRC-BRE19-409). . 31 (12_Supplement): P2¿09¿27,
  3. Krishnamurthy J, Elsayed L, Reed E, Modi S, Tandra P, Copur M, Samson K (2025). Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide with Trastuzumab in Stage I-III Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer. 31 (12_Supplement): P4¿05¿05,
  4. Cartwright SB, Jiang H, Elsayed L, Modi S, Asif S, Kesireddy M, Yellala A, Wahl AO, Maxwell JE, Wagner DG, Lele SM, Krishnamurthy J, Santamaria-Barria J (2024). Poor Response of Metaplastic Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy: An Unmet Oncological Need.
  5. Davis A, Luo J, Zheng T, Tan L, Wang A, Suresh R, Ademuyiwa F, Rigden C, Rearden T, Clifton K, Weilbaecher K, Frith A, Tandra P, Summa T, Haas B, Thomas S, Hernandez-Aya L, Peterson L, Luo S, King B, Jia S, Yu J, Du P, Krishnamurthy J, Ma C (2022). Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6i). 82(4_Supplement), 2-07-01.
  6. Chan N, Moore D, Tandra P, Rana J, Omene C, George M, Krishnamurthy J, Desai S, Patel N, Wang Y, Bicomong M, Tan X, Hirshfield K, Ganesan S, Toppmeyer (2022). A phase II study of pembrolizumab plus fulvestrant in hormone receptor positive, HER-2 negative advanced/metastatic breast cancer patients. 82(4_Supplement), OT1-17-02.
  7. Krishnamurthy J, Luo J, Suresh R, Ademuyiwa F, Rigden C, Reardon T, Clifton K, Weilbaecher K, Frith A, Roshal A, Tandra P, Cherian M, Summa T, Thomas S, Hernandez-Aya L, Bergqvist M, Peterson L, Ma C (2021). Abstract PS12-02: Safety and efficacy of an alternative schedule of palbociclib (PAL) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) and the utility of serum thymidine kinase 1 (sTK1) activity in predicting PAL response. 81(4_Supplement), S12-02.
  8. Krishnamurthy J, Luo J, Suresh R, Ademuyiwa F, Rigden C, Reardon T, Weilbaecher K, Frith A, Roshal A, Tandra P, Cherian M, Summa T, Thomas S, Hernandez-Aya L, Peterson L, Ma (2020). A phase II trial assessing the safety of an alternative dosing schedule of palbociclib (palbo) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC). 80(4_Supplement), 1-19-13.
  9. Harter D, Tseng Y, Krishnamurthy J, Tandra (2020). Can IHC4 profile predict a low Oncotype recurrence score (RS) in clinically low risk breast tumors?. 33(Suppl 2), 240¿443.

Other

  1. Krishnamurthy (2019). Annual Mammogram Plays Key Role in Early Breast Cancer Detection and Cancer Eradication.

Video/Film/CD/Web/Podcast

  1. Krishnamurthy (2026). Krishnamurthy J. Female Survivor Advantage Narrows in Midlife due to Cancer.
  2. Krishnamurthy (2024). Krishnamurthy J. Metastatic Triple Negative Breast Cancer - Selection, Sequencing and Treatment Paradigm with Case Examples.
  3. Krishnamurthy (2024). Krishnamurthy J. Frontline Palbociclib Opens the Door to Subsequent CDK 4/6 Inhibition in Metastatic Breast Cancer.
  4. Krishnamurthy (2024). Krishnamurthy J. Dr. Krishnamurthy on Treatment Sequencing based on Mutation Status in HR+/Her2- Breast Cancer.
  5. Krishnamurthy (2024). Krishnamurthy J. Category 1 Recommendation of Ribociclib Plus an AI Represents a Huge advancement in Breast Cancer.
  6. Krishnamurthy J (2023). Krishnamurthy J. Novel Sequencing Strategies May Expand Localized and Metastatic Breast Cancer Treatment Landscapes.
  7. Krishnamurthy (2021). Krishnamurthy J. Advancement in management of breast cancer, televised interview with local ABC affiliate network, KETV.
  8. Krishnamurthy (2017). Krishnamurthy J. Male breast cancer awareness, televised interview with local ABC affiliate network, KETV.

News & Podcasts

Huntsman Cancer Institute News